Maternal folic acid supplementation and dietary folate intake and congenital heart defects

Baohong Mao¹, Jie Qiu¹, Nan Zhao², Yawen Shao¹, Wei Dai¹, Xiaochun He¹, Hongmei Cui¹, Xiaojuan Lin¹, Ling Lv¹, Zhongfeng Tang¹, Sijuan Xu¹, Huang Huang², Min Zhou¹, Xiaoying Xu¹, Weitao Qiu¹, Qing Liu¹*, Yawei Zhang²*

¹ Gansu Provincial Maternity and Child Care Hospital, Qilihe District, Lanzhou, Gansu Province, China, ² Yale University School of Public Health, New Haven, Connecticut, United States of America

* These authors contributed equally to this work.
* yawei.zhang@yale.edu (YZ); 2305470816@qq.com (QL)

Abstract

Background

It has been reported that folic acid supplementation before and/or during pregnancy could reduce the risk of congenital heart defects (CHDs). However, the results from limited epidemiologic studies have been inconclusive. We investigated the associations between maternal folic acid supplementation, dietary folate intake, and the risk of CHDs.

Methods

A birth cohort study was conducted in 2010–2012 at the Gansu Provincial Maternity & Child Care Hospital in Lanzhou, China. After exclusion of stillbirths and multiple births, a total of 94 births were identified with congenital heart defects, and 9,993 births without any birth defects. Unconditional logistic regression was used to estimate the associations.

Results

Compared to non-users, folic acid supplement users before pregnancy had a reduced risk of overall CHDs (OR: 0.42, 95% CI: 0.21–0.86, \(P_{\text{trend}} = 0.025\)) after adjusted for potential confounders. A protective effect was observed for certain subtypes of CHDs (OR: 0.37, 95% CI: 0.16–0.85 for malformation of great arteries; 0.26, 0.10–0.68 for malformation of cardiac septa; 0.34, 0.13–0.93 for Atrial septal defect). A similar protective effect was also seen for multiple CHDs (OR: 0.49, 95% CI: 0.26–0.93, \(P_{\text{trend}} = 0.004\)). Compared with the middle quartiles of dietary folate intake, lower dietary folate intake (<149.88 μg/day) during pregnancy were associated with increased risk of overall CHDs (OR: 1.63, 95% CI: 1.01–2.62) and patent ductus arteriosus (OR: 1.85, 95% CI: 1.03–3.32). Women who were non-user folic acid supplement and lower dietary folate intake have almost 2-fold increased CHDs risk in their offspring.
Conclusions

Our study suggested that folic acid supplementation before pregnancy was associated with a reduced risk of CHDs, lower dietary folate intake during pregnancy was associated with increased risk. The observed associations varied by CHD subtypes. A synergistic effect of dietary folate intake and folic acid supplementation was also observed.

Introduction

Congenital heart defects (CHDs) are among the major birth defects in newborns and affect approximately 4 to 10 per 1,000 live births [1–3]. The CHD prevalence had increased substantially, from 0.6 per 1,000 live births in 1930–1934 to 9.1 per 1,000 live births in 2005–2009 [3]. The disease burden caused by CHDs had reached 224 Disability-adjusted life years (DALYs) per 100,000 persons, accounts for 39.72 percent of all congenital anomalies worldwide based Global Burden of Disease Study on 2010 [4]. In china the prevalence of CHDs are particularly high and become the most frequent type of birth defects with the prevalence of 28.82 per 10,000 persons in 2009 [5]. The etiology of CHDs is poorly understood, and thus the prevention measures have been limited.

Two recent studies reported a reduced rate of CHDs in Quebec (Canada) and Atlanta (USA) over the past years and suggested that folic acid fortification of grain products might play a role [6, 7]. Epidemiological studies that investigated the association between folic acid intake and the risk of CHDs have reached conflicting results. Twelve studies found that folic acid supplementation before and/or during pregnancy reduced the risk of CHDs [8–19], six studies reported no association between folic acid supplements and CHD risk [20–25], while one study found a significantly increased risk of CHDs associated with folic acid supplement use[26]. Three studies investigated dietary folate intake and risk of CHDs and found no association [27–29]. No study has investigated folic acid supplementation and dietary folate intake simultaneously in relation to the risk of CHDs. To further clarify the role of folic acid supplements and dietary folate intake, we analyzed data from a birth cohort study conducted in Lanzhou, China.

Materials and methods

Study population

A birth cohort study was conducted at the Gansu Provincial Maternity and Child Care Hospital during 2010–2012 in Lanzhou, China [30, 31]. In brief, after obtaining written consent, eligible pregnant women who came to the hospital for delivery were interviewed by trained study interviewers using a standardized and structured questionnaire to collect the detail information on demographics, residential history, smoking and alcohol consumption, occupational history, medical history, reproductive history, nutrient supplements, and diet. Information on birth outcomes and maternal complications was abstracted from the medical records. A total of 10,542 pregnant women (73.42%) were completed the questionnaire. All study procedures were approved by the Human Investigation Committees at the Gansu Provincial Maternity and Child Care Hospital and Yale University.

After exclusion of multiple births, stillbirths and/or births with other birth defects (non-CHDs), 10,087 singleton live births were included in the study (As shown in Fig 1).
Classification of congenital heart defects

Each congenital heart defect was described as “Isolated”, “Multiple” or “Syndrome” based on the defect’s complexity. The isolated CHD category was described either an isolated CHD or a well defined single entity (such as tetralogy of Fallot). The multiple CHD category was described the infants with more than one distinct CHDs (eg, atrial septal defect with patent ductus arteriosus) and without any non-CHDs congenital anomalies. The Syndrome CHD category was described the infants with distinct CHDs associated with any non-CHD congenital anomalies. All of CHDs were classified into three subgroups by International Classification of Diseases (ICD)-10 code (Q20–Q28) and the clinical phenotype: (1) Congenital malformations of great arteries (ICD 10: Q25), including patent ductus arteriosus (PDA), coarctation of aorta, stenosis of pulmonary artery, atresia of pulmonary artery, and other congenital malformations of great arteries. (2) Congenital malformations of cardiac septa (ICD 10: Q21), including atrioventricular septal defects (AVSDs), ventricular septal defects (VSDs), atrial septal defects (ASDs), tetralogy of Fallot, aortopulmonary septal defect, and other congenital malformations of cardiac septa. (3) Other CHDs, including congenital malformations of cardiac chambers and connections, congenital malformations of aortic and mitral valves, other congenital malformations of heart, etc. Among 10,087 individuals, 94 women had live-born singleton infants with CHDs, 43 infants had isolated defect, 46 infants had multiple defect, and other 5 infants had syndrome defect. Among 94 CHDs, 69 were congenital malformations of the great arteries, 58 were congenital malformations of cardiac septa, and 18 were other congenital heart defects.
Folic acid supplementation and dietary folate intake

The process of data collection on folic acid supplementation and dietary folate intake has been described previously [31, 32]. Briefly, four time periods information about folic acid supplements and dietary folate intake were collected: before conception (12 months before pregnancy), first trimester (1–13 weeks), second trimester (14–27 weeks) and third trimester (>27 weeks). In every period, frequency and duration of folic acid supplement alone and folic acid-containing multivitamins were ascertained. Nonusers were defined as those who never took folic acid supplement alone or folic acid-containing multivitamins before conception and/or during pregnancy, users were defined as those who took folic acid supplement alone or folic acid-containing multivitamins before conception and/or during pregnancy. Dietary information was collected via a semiquantitative food frequency questionnaire (including 39 food items) for the four time periods: before conception (12 months before pregnancy), first trimester (1–13 weeks), second trimester (14–27 weeks) and third trimester (>27 weeks). Daily dietary folate intake for each time period was estimated from the frequency of consumption and portion size of food items using the Chinese Standard Tables of Food Consumption [33]. Daily dietary folate intake during pregnancy was estimated by averaging the intake from three trimesters.

Statistical analysis

Distributions of sociodemographic and lifestyle characteristics between cases and controls were compared using χ2-tests. Unconditional logistic regression models were used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for the association of folic acid supplements or dietary folate intake and the risk of CHD and its clinical subtypes. We classified duration of the folic acid supplements into two levels (≤12 weeks, >12 weeks) by midpoint of duration of use, to indicate the low and high levels. Dose response relationship (P for trend) was estimated by including a categorical variable (values 0, 1, 2 representing non-users, low and high level users, respectively). Dietary folate intake was categorized as <25th percentile, 25th to 75th percentile, and ≥75th percentile, based on the distribution of each duration of dietary folate intake among controls. In the final models, we adjusted for potential confounding variables, including maternal age, education level (<college, ≥college), family monthly income per capita (<3000, ≥3000 RMB), employment (never, employed during pregnancy, unemployed during pregnancy), maternal BMI (<18.5, 18.5–23.9, ≥24.0 kg/m²), gestational diabetes (yes or no), abortion history (yes or no), parity (primipara, multipara). Additional adjustment for alcohol drinking, active and passive smoking, infant gender, maternal anemia did not result in material changes of the observed associations, thus these covariates were not included in the final models. All analyses were performed using SAS 9.3 software (SAS Institute Inc., Cary, NC, USA) and P < 0.05 and 95% CI excluding 1.0 was considered statistically significant.

Results

Among 10,087 individuals, 94 women had live-born singleton infants with CHDs. Among those infants, 43 had isolated defect, 46 had multiple defects, and 5 had syndromic defects. Specifically, 69 were congenital malformations of the great arteries, 58 were congenital malformations of cardiac septa, and 18 were other CHDs.

As shown in Table 1, compared with mothers whose infants did not have CHDs, mothers of infants with CHDs were more likely to have gestational diabetes, have lower dietary folate intake and family income. Distributions of maternal age, education, unemployment, smoking,
Table 1. Maternal characteristics of cases and controls, China, 2010–2012.

| Characteristics                        | controls (n = 9993) | cases (n = 94) | P-value |
|----------------------------------------|--------------------|----------------|---------|
| Maternal age                           |                    |                |         |
| <25                                    | 1601               | 19             | 1.17    | 0.084  |
| 25–29                                  | 3756               | 25             | 0.66    |        |
| ≥30                                    | 4636               | 50             | 1.07    |        |
| Highest education level                |                    |                |         |
| < College                              | 6095               | 62             | 1.01    | 0.239  |
| ≥College                               | 3716               | 29             | 0.99    |        |
| Missing                                | 182                | 3              | 1.62    |        |
| Monthly income per capita(RMB)         |                    |                |         |
| < 3000                                 | 5037               | 55             | 1.08    | 0.039  |
| ≥3000                                  | 4005               | 27             | 0.67    |        |
| Missing                                | 951                | 12             | 1.25    |        |
| Maternal employment                   |                    |                |         |
| never employ                           | 3271               | 35             | 1.06    | 0.351  |
| employed during pregnancy              | 5155               | 49             | 0.94    |        |
| unemployed during pregnancy            | 1567               | 10             | 0.63    |        |
| Smoking (passive and active)           |                    |                |         |
| No                                     | 8037               | 75             | 0.92    | 0.876  |
| Yes                                    | 1956               | 19             | 0.96    |        |
| Alcohol consumption during pregnancy   |                    |                |         |
| No                                     | 9973               | 94             | 0.93    | 0.829* |
| Yes                                    | 20                 | 0              | 0.00    |        |
| BMI (kg/m²)                            |                    |                |         |
| <18.5                                  | 2379               | 24             | 1.00    | 0.315  |
| 18.5–23.9                              | 6561               | 56             | 0.85    |        |
| ≥24.0                                  | 1053               | 14             | 1.31    |        |
| Gestational diabetes                   |                    |                |         |
| No                                     | 9898               | 88             | 0.88    | <0.001 |
| Yes                                    | 95                 | 6              | 5.94    |        |
| Abortion history                       |                    |                |         |
| No                                     | 8685               | 86             | 0.98    | 0.189  |
| Yes                                    | 1308               | 8              | 0.61    |        |
| Parity                                 |                    |                |         |
| Primipara                              | 7212               | 65             | 0.89    | 0.515  |
| Multipara                              | 2781               | 29             | 1.03    |        |
| Folic acid supplement                  |                    |                |         |
| Nonusers                               | 2676               | 33             | 1.22    | 0.069  |
| Users                                  | 7317               | 61             | 0.83    |        |
| Dietary folate intake(μg/day)          |                    |                |         |
| <25th percentile                       | 2491               | 34             | 1.35    | 0.043  |
| 25th-75th percentile                   | 5002               | 40             | 0.79    |        |
| ≥75th percentile                       | 2500               | 20             | 0.79    |        |

Calculated by χ² analysis without accounting for missing data
* Fisher exact test

https://doi.org/10.1371/journal.pone.0187996.t001
alcohol consumption, abortion history, and parity were similar between mothers whose infants with and without CHDs.

Compared to nonusers, ever folic acid supplement users did not experience a significantly reduced risk of CHDs (OR: 0.81, 95% CI: 0.51–1.29, Table 2). While a suggestive reduced risk of CHDs was observed for longer term users (OR = 0.57, 95%CI: 0.34–0.95), however, the protective effect was attenuated after additional adjustment for dietary folate intake (OR: 0.64, 95%CI: 0.38–1.08). After stratifying by time periods of use of folic acid supplements, significantly protective effect was observed for those who took supplements before pregnancy (OR: 0.42, 95% CI: 0.21–0.86) with a significant dose-response for duration of use ($P$ for trend = 0.025). No significant association was observed among women who took supplements during pregnancy. Compared with the middle quartiles (25th to 75th) of dietary folate intake, an increased risk was observed for those who were in the lowest quartile of dietary folate intake during pregnancy (OR: 1.63, 95% CI: 1.01–2.62). No significant association was observed between dietary folate intake before pregnancy and risk of CHDs.

After stratifying by CHD subtypes, similar associations with folic acid supplements were observed for congenital malformation of great arteries and congenital malformation of cardiac

Table 2. Associations between folate intake and the risk of overall congenital heart defects, China, 2010–2012.

| Folic acid/folate intake duration | Controls (n = 9993) | Overall Congenital Heart Defects |
|----------------------------------|---------------------|----------------------------------|
|                                  | Cases(n = 94)       | OR $^a$ (95% CI)                 | OR $^b$ (95% CI) |
| Folic acid supplement            |                     |                                  |                   |
| Nonusers                         | 2676                | 33                               | 1.00              | 1.00              |
| Users                            | 7317                | 61                               | 0.73(0.46–1.14)   | 0.81(0.51–1.29)   |
| ≤12 weeks                        | 2385                | 28                               | 1.00(0.60–1.68)   | 1.11(0.66–1.89)   |
| >12 weeks                        | 4932                | 33                               | 0.57(0.34–0.95)   | 0.64(0.38–1.08)   |
| $P$ for trend                    | 0.009               |                                  | 0.053             |
| Before pregnancy                 | 3081                | 14                               | 0.38(0.19–0.76)   | 0.42(0.21–0.86)   |
| ≤8 weeks                         | 1389                | 6                                | 0.36(0.14–0.89)   | 0.40(0.16–1.03)   |
| >8 weeks                         | 1692                | 8                                | 0.40(0.17–0.93)   | 0.43(0.18–1.02)   |
| $P$ for trend                    | 0.005               |                                  | 0.025             |
| During pregnancy                 | 6814                | 60                               | 0.77(0.49–1.20)   | 0.87(0.55–1.38)   |
| ≤12 weeks                        | 2511                | 29                               | 0.95(0.57–1.58)   | 1.06(0.63–1.79)   |
| >12 weeks                        | 4303                | 31                               | 0.63(0.37–1.06)   | 0.71(0.42–1.22)   |
| $P$ for trend                    | 0.035               |                                  | 0.146             |
| Dietary folate intake(μg/day)    |                     |                                  |                   |
| Before pregnancy                 | 2498                | 32                               | 1.42(0.88–2.27)   | 1.39(0.86–2.23)   |
| <115.97                          | 4997                | 42                               | 1.00              | 1.00              |
| 115.97, 221.03                   | 2498                | 20                               | 0.96(0.56–1.64)   | 0.93(0.54–1.59)   |
| ≥221.03                          |                      |                                  | 0.157             | 0.152             |
| $P$ for trend                    |                      |                                  |                   |
| During pregnancy                 | 2498                | 34                               | 1.67(1.04–2.67)   | 1.63(1.01–2.62)   |
| <149.88                          | 4990                | 39                               | 1.00              | 1.00              |
| 149.88, 266.35                   | 2505                | 21                               | 1.08(0.63–1.86)   | 1.06(0.62–1.81)   |
| ≥266.35                          |                      |                                  | 0.099             | 0.105             |

$^a$ Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity.

$^b$ Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity, dietary folate intake or folic acid supplement.

https://doi.org/10.1371/journal.pone.0187996.t002
Lower dietary folate intake during pregnancy was associated with a suggestive increased risk of congenital malformation of great arteries (OR: 1.71 95% CI: 0.97–2.99) but not congenital malformation of cardiac septa (OR: 1.24, 95% CI: 0.67–2.32).

Associations between folate intake and risk of both patent ductus arteriosus (PDA) and atrial septal defect (ASD) were shown in Table 4. Compared to nonusers, a suggestive reduced risk of PDA was observed for longer term folic acid supplement users (OR 0.55, 95% CI: 0.29–

| Folic acid/folate intake duration | Controls (n = 9993) | Congenital malformation of great arteries Cases (n = 69) | ORa (95% CI) | ORb (95% CI) | Congenital malformation of cardiac septa Cases (n = 58) | ORa (95% CI) | ORb (95% CI) |
|----------------------------------|---------------------|--------------------------------------------------------|---------------|---------------|--------------------------------------------------------|---------------|---------------|
| Folic acid supplement            |                     |                                                        |               |               |                                                        |               |               |
| Nonusers                         | 2676                | 27                                                     | 1.00          | 1.00          | 24                                                     | 1.00          | 1.00          |
| Users                            | 7317                | 42                                                     | 0.60(0.36–1.01)| 0.67(0.40–1.14)| 34                                                     | 0.54(0.31–0.95)| 0.62(0.35–1.10)|
| ≤ 12 weeks                       | 2385                | 20                                                     | 0.88(0.48–1.59)| 0.97(0.53–1.78)| 15                                                     | 0.75(0.39–1.45)| 0.84(0.43–1.65)|
| >12 weeks                        | 4932                | 22                                                     | 0.45(0.25–0.82)| 0.50(0.27–0.93)| 19                                                     | 0.43(0.23–0.82)| 0.50(0.26–0.96)|
| P for trend                       |                     | 0.003                                                   | 0.015          | 0.004         | 0.027                                                   |               |               |
| Before pregnancy                 | 3081                | 10                                                     | 0.32(0.14–0.73)| 0.37(0.16–0.85)| 7                                                       | 0.24(0.09–0.61)| 0.26(0.10–0.68)|
| ≤ 8 weeks                        | 1389                | 4                                                      | 0.29(0.10–0.87)| 0.34(0.11–1.05)| 3                                                       | 0.23(0.06–0.80)| 0.25(0.07–0.90)|
| >8 weeks                         | 1692                | 6                                                      | 0.35(0.13–0.93)| 0.40(0.15–1.06)| 4                                                       | 0.25(0.08–0.80)| 0.27(0.08–0.87)|
| P for trend                       |                     | 0.006                                                   | 0.029          | 0.003         | 0.011                                                   |               |               |
| During pregnancy                 | 6814                | 41                                                     | 0.63(0.38–1.06)| 0.71(0.42–1.21)| 33                                                      | 0.57(0.33–1.00)| 0.66(0.37–1.17)|
| ≤ 12 weeks                       | 2701                | 22                                                     | 0.85(0.48–1.53)| 0.95(0.52–1.72)| 16                                                      | 0.70(0.37–1.35)| 0.80(0.41–1.55)|
| >12 weeks                        | 4113                | 19                                                     | 0.47(0.25–0.88)| 0.53(0.28–1.01)| 17                                                      | 0.47(0.24–0.92)| 0.55(0.28–1.09)|
| P for trend                       |                     | 0.007                                                   | 0.033          | 0.012         | 0.064                                                   |               |               |
| Dietary folate intake(μg/day)    |                     |                                                        |               |               |                                                        |               |               |
| Before pregnancy                 |                     |                                                        |               |               |                                                        |               |               |
| <115.97                          | 2498                | 22                                                     | 1.26(0.72–2.19)| 1.21(0.69–2.12)| 20                                                      | 1.55(0.84–2.85)| 1.48(0.80–2.74)|
| 115.97, 221.03                   | 4997                | 32                                                     | 1.00          | 1.00          | 24                                                      | 1.00          | 1.00          |
| ≥221.03                          | 2498                | 15                                                     | 0.94(0.50–1.75)| 0.88(0.47–1.65)| 14                                                      | 1.16(0.59–2.26)| 1.08(0.55–2.12)|
| P for trend                       |                     | 0.334                                                   | 0.319          | 0.377         | 0.368                                                   |               |               |
| During pregnancy                 |                     |                                                        |               |               |                                                        |               |               |
| <149.88                          | 2498                | 25                                                     | 1.78(1.02–3.11)| 1.71(0.97–2.99)| 18                                                      | 1.31(0.71–2.43)| 1.24(0.67–2.32)|
| 149.88, 266.35                   | 4990                | 27                                                     | 1.00          | 1.00          | 26                                                      | 1.00          | 1.00          |
| ≥266.35                          | 2505                | 17                                                     | 1.27(0.69–2.35)| 1.22(0.66–2.26)| 14                                                      | 1.08(0.56–2.10)| 1.02(0.53–1.99)|
| P for trend                       |                     | 0.215                                                   | 0.227          | 0.562         | 0.595                                                   |               |               |

a Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity.

b Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity, dietary folate intake or folic acid supplement.
1.04) with a significant dose-response ($P$ for trend = 0.041), and a significantly reduced risk of ASD was observed for those who took supplements before pregnancy (OR: 0.34, 95% CI: 0.13–0.93). Compared with the middle quartiles of dietary folate intake, lower dietary folate intake during pregnancy increased the risk of PDA (OR: 1.85, 95% CI: 1.03–3.32), but not ASD (OR: 1.44, 95% CI: 0.72–2.87).

We further analyzed the data by multiple CHDs and isolated CHDs (Table 5). Compared with nonusers, significantly protective effect of folic acid supplement use was observed for multiple CHDs (OR 0.49, 95% CI 0.26–0.93) with a significant dose-response ($P$ for trend = 0.004). The associations were similar for different time periods of use of folic acid supplements. No significant association was observed between folic acid supplement use and isolated CHD. A borderline significant increase in risk of multiple CHDs was found among women who had lower dietary folate intake before pregnancy (OR: 1.97, 95% CI 0.98–3.97). Dietary folate intake was not associated with isolated CHD.

A joint effect between folic acid supplement use and dietary folate intake on the risk of CHDs were analyzed. However, there was no significant interaction between folic acid

### Table 4. Associations between folate intake and the risk of patent ductus arteriosus and atrial septal defect, China, 2010–2012.

| Dietary folate intake(μg/day) | Controls (n = 9993) | Patent ductus arteriosus | Atrial septal defect |
|-------------------------------|---------------------|--------------------------|---------------------|
|                               | (n = 65)            | OR$^a$ (95% CI)          | OR$^b$ (95% CI)     |
|                               | (n = 46)            |                          | (n = 46)            |
| Before pregnancy              |                     |                          | (n = 46)            |
| <115.97                       | 2498                | 1.16(0.65–2.07)          | 1.13(0.63–2.02)     |
| 115.97, 221.03                | 4997                | 1.00                     | 1.00                |
| ≥221.03                       | 2498                | 0.91(0.48–1.73)          | 0.87(0.46–1.66)     |
| $P$ for trend                 | 0.469               | 0.451                    | 0.594               |
| During pregnancy              |                     |                          | (n = 46)            |
| <149.88                       | 2498                | 1.91(1.07–3.40)          | 1.85(1.03–3.32)     |
| 149.88, 266.35                | 4990                | 1.00                     | 1.00                |
| ≥266.35                       | 2505                | 1.44(0.77–2.71)          | 1.40(0.74–2.64)     |
| $P$ for trend                 | 0.312               | 0.321                    | 0.431               |

$^a$ Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history. Parity.

$^b$ Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity, dietary folate intake or folic acid supplement

https://doi.org/10.1371/journal.pone.0187996.t004
supplementation and dietary folate intake on the risk of CHDs (data not shown). Potential
effect modifications of maternal age on the associations between folate intake and risk of
CHDs were also analyzed and didn’t observe significant findings (data not shown). Addition-
ally, we observed no interaction between gestational diabetes and folic acid supplement use
and dietary folate intake (P for interaction = 0.38 and 0.09, respectively).

Discussion

Our study suggested that folic acid supplements before pregnancy were associated with a
reduced risk of CHDs and the reduced risk varied by CHD subtypes. Our study also suggested
that lower dietary folate intake during pregnancy increased the risk of CHDs and the risk var-
ied by CHD subtype. A suggestive joint effect between folic acid supplement and dietary folate
intake before pregnancy on the risk of CHD was also observed in our study.

There is biologic plausibility underlying the association between folate and CHD. Accumu-
lating evidence suggests that inadequate folate status prevent the re-methylation of 5-methyl-

Table 5. Associations between folate intake and the risk of multiple and isolated congenital heart defects, China, 2010–2012.

| Folic acid/folate intake duration | Controls (n = 9993) | Multiple CHDs | Isolated CHDs |
|---------------------------------|-------------------|---------------|---------------|
|                                 | Cases (n = 46) | $OR^a$ (95% CI) | $OR^b$ (95% CI) | Cases (n = 43) | $OR^a$ (95% CI) | $OR^b$ (95% CI) |
| Folic acid supplement           |                  |               |               |
| Nonusers                        | 2676             | 22            | 1.00          | 1.00          | 1.00          | 1.00          |
| Users                           | 7317             | 24            | 0.41(0.22–0.77) | 0.49(0.26–0.93) | 33            | 1.32(0.63–2.75) | 1.39(0.66–2.99) |
| ≤12 weeks                       | 2385             | 12            | 0.66(0.32–1.35) | 0.76(0.36–1.59) | 14            | 1.62(0.71–3.69) | 1.70(0.74–3.89) |
| >12 weeks                       | 4932             | 12            | 0.29(0.14–0.61) | 0.34(0.16–0.74) | 19            | 1.13(0.50–2.53) | 1.19(0.53–2.69) |
| P for trend                     |                  |               |               |
|                                | 0.000            | 0.004         |               |               | 0.961         | 0.831         |
| Before pregnancy                |                  |               |               |
| <115.97                         | 2498             | 18            | 2.11(1.05–4.22) | 1.97(0.98–3.97) | 14            | 1.17(0.59–2.30) | 1.18(0.60–2.33) |
| 115.97, 221.03                  | 4997             | 16            | 1.00          | 1.00          | 22            | 1.00          | 1.00          |
| ≥221.03                         | 2498             | 12            | 1.45(0.68–3.10) | 1.31(0.61–2.82) | 7             | 0.67(0.28–1.58) | 0.69(0.29–1.62) |
| P for trend                     | 0.234            | 0.232         |               |               | 0.299         | 0.304         |
| During pregnancy                |                  |               |               |
| <149.88                         | 2498             | 16            | 1.71(0.85–3.42) | 1.57(0.78–3.16) | 17            | 1.91(0.96–3.78) | 1.94(0.98–3.85) |
| 149.88, 266.35                  | 4990             | 18            | 1.00          | 1.00          | 17            | 1.00          | 1.00          |
| ≥266.35                         | 2505             | 12            | 1.32(0.63–2.78) | 1.22(0.58–2.56) | 9             | 1.11(0.49–2.52) | 1.14(0.50–2.58) |
| P for trend                     | 0.412            | 0.451         |               |               | 0.174         | 0.172         |

a Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity.
b Adjusted for maternal age, education level, family monthly income per capita, employment, maternal BMI, diabetes, abortion history, Parity, dietary folate intake or folic acid supplement

https://doi.org/10.1371/journal.pone.0187996.t005
tetrahydrofolate and lead to the accumulation of homocysteine[34]. Excessive homocysteine results in abnormalities of cardiac neural crest cell migration, differentiation, dispersal, and cell cycle progression, which disrupt the development of cardiac neural crest and lead to the occurrence of CHDs [35, 36]. Adequate folate is necessary for normal development of cardio system of the fetus.

Earlier epidemiological researches investigating the associations between folic acid supplements and the risk of CHDs provided inconsistent results. Five case-control studies [13, 20, 23, 24, 26] reported that take folic acid/ multivitamin supplements had no association with overall CHDs, other four studies [9, 10, 12, 16] reported that folic acid/ multivitamin supplementation could reduce the risk of overall CHDs which consistent with our results. Li et al [16] conducted a hospital based case-control study (2010–2011) in Chengdu (China) including 358 cases and 422 controls and found that pregnant woman who reported multivitamin (containing folic acid) supplementation during the period from three months prior to conception to two months after conception were less likely to have offspring with CHDs (OR = 0.52, 0.34–0.78). Botto et al[10] carried out a population based case-control study in Atlanta including 494 cardiac defects cases and 1610 controls based on Atlanta Birth Defects Research (1968–1980), which found that pregnant woman who regular use of multivitamins from three months before pregnancy through the first three months of pregnancy cut by almost one-quarter risk of overall CHDs(OR = 0.76, 0.60–0.97). Czeizel et al [12] conducted a cohort controlled trial study(1993–1996) in Budapest (Hungary), which found that woman who take multivitamin (containing folic acid) supplementation from one month before conception to three month after conception reduced the risk of overall CHDs(31/3056 vs 50/3056, OR = 0.60, 0.38–0.96). Czeizel [9] carried out a randomized controlled trial (1984–1991) in Budapest (Hungary) to evaluate the efficacy of trace element supplementation in reduction of the occurrence of neural tube defects, which also found that woman who take multivitamin (containing folic acid) supplementation during three month before pregnancy reduced the occurrence of CHDs. However, when assessed the association between folic acid supplementation and CHDs, none of these studies considered the effect of dietary folate intake on the associations between folic acid supplementation and CHDs. Our results showed that the associations of folic acid supplementation with CHDs attenuated when dietary folate intake were included in the model as well as vice versa.

Our study found that longer duration of supplementation had a beneficial effect on reduction of overall CHDs risk. Only one early study [16] explored the association by duration of maternal folic acid supplementation and the results were consistent with our study.

Our study found significant associations between folic acid supplementation and certain subtypes of CHDs, including congenital malformation of great arteries, congenital malformation of cardiac septa, ASD, and multiple CHDs, which were consistent with several previous studies [10, 13, 14, 18], but not all [9, 12, 26]. Botto et al[10] found that regular use of folic acid containing multivitamins from three months before pregnancy through the first three months of pregnancy was associated with a 41% reduced risk of cardiac septal defects, but not ASD. Van-Beynum et al.[13] found a 38% reduced risk of septal defects and a 46% reduced risk of ASD associated with folic acid supplement intake from 4 weeks before conception to 8 weeks after conception, but no association with AVSD and PDA. Bean et al [14] reported that lack of maternal folic acid supplementation before and during pregnancy increased the risk of septal defects in infants. Vereczkey et al [18] found a 49% reduced risk of AVSD associated with folic acid supplements from the preconception period to the first trimester of pregnancy. Leirgul et al [26] reported an increased risk for isolated septal defects if mothers used folic acid supplements before and during pregnancy. Czeizel et al.[9, 12] found no significant association was exist between multiple CHDs and folic acid supplements use. Variations in study populations
(American, Hungarian, Dutch, Norwegians, Chinese), the time for initiating supplementation (before and/or during pregnancy) may have contributed to the inconsistent results.

Our study also found lower dietary folate intake (<149.88 μg/day) increased the risk of CHDs and PDA subtype compared with the middle quartiles (25th to 75th) during pregnancy. Few early studies investigated dietary folate intake and risk of CHDs and have reached inconsistent results [27–29]. Smedts et al. [28] reported lower dietary folate intake(<165 μg/day) was not associated with the risk of CHDs. Verkleij-Hagoort et al. [29] also reported no significant association between lower dietary folate intake (<117.6 μg/day) and the risk of CHDs. Shaw et al [27] reported lower dietary folate intake(<293.8 μg/day) associated with increased risk of d-transposition of great arteries but not tetralogy of Fallot. It is challenge to make comparison among these studies due to different cut-off levels of dietary folate intake being used by different studies. In addition, background dietary folate intake might also varied across populations.

Strengths and limitations should be considered when interpreting the study results. Our study collected detailed information on both folic acid supplementation and dietary folate intake, which allowed us to control for each other. While many important confounding factors have been adjusted for, potential residual confounding cannot be entirely ruled out. Information on dietary intake and folic acid supplements were collected through in-person interview at delivery, potential recall bias might play a role. However, the relationships between folic acid supplementation, dietary folate intake, and risk of CHDs have not been well-established, and were unlikely to be known by the general public. Therefore, if there was any recall bias it was likely to be non-differential and resulted in underestimation of the observed associations. The statistical power for CHD subtypes were limited due to the relatively small sample size. While our study was a hospital-based and might affect the generalizability, the prevalence of CHDs (9.3 per 1000 live births) in our study population was comparable to the reported prevalence in various Chinese populations [37–40].

In conclusion, our study results suggest that folic acid supplementation before pregnancy reduces the risk of CHDs and lower dietary folate intake during pregnancy increases the risk of CHDs. Future larger studies with greater statistical power are warranted to elucidate the associations by CHD subtypes and identify women who would benefit the most from folic acid supplements. Finally, our findings have important public health implications and may facilitate the acceptance of taking folic acid supplements during preconception and pregnancy and the increase in dietary folate intake during pregnancy.

**Author Contributions**

**Data curation:** Nan Zhao, Huang Huang.

**Formal analysis:** Baohong Mao, Nan Zhao, Yawen Shao, Wei Dai, Huang Huang.

**Funding acquisition:** Qing Liu, Yawei Zhang.

**Investigation:** Xiaochun He, Hongmei Cui, Xiaojuan Lin, Ling Lv, Zhongfeng Tang, Sijuan Xu, Min Zhou, Xiaoying Xu, Weitao Qiu.

**Project administration:** Yawei Zhang.

**Resources:** Jie Qiu.

**Supervision:** Jie Qiu, Qing Liu, Yawei Zhang.

**Writing – original draft:** Baohong Mao, Jie Qiu, Qing Liu, Yawei Zhang.

**Writing – review & editing:** Nan Zhao, Yawei Zhang.
References

1. Oyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PKA, Melbye M. National time trends in congenital heart defects, Denmark, 1977–2005. American Heart Journal. 2009; 157(3):467–73. https://doi.org/10.1016/j.ahj.2008.10.017 PMID: 19249416.

2. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population—Changing prevalence and age distribution. Circulation. 2007; 115(2):163–72. https://doi.org/10.1161/CIRCULATIONAHA.106.627224 PMID: 17210844.

3. van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JUM, et al. Birth Prevalence of Congenital Heart Disease Worldwide A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology. 2011; 58(21):2241–7. https://doi.org/10.1016/j.jacc.2011.08.025 PMID: 22078432.

4. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. LANCET. 2012; 380(9859):2197–223. https://doi.org/10.1016/S0140-6736(12)61689-4 PMID: 23245608.

5. Dai L, Zhu J, Liang J, Wang Y-P, Wang H, Mao M. Birth defects surveillance in China. World Journal of Pediatrics. 2011; 7(4):302–10. https://doi.org/10.1007/s12519-011-0326-0 PMID: 22015723.

6. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. Br Med J. 2009; 338:8. https://doi.org/10.1136/bmj.b1673 PMID: 19436079.

7. Bjornard K, Riehle-Colarusso T, Gilboa SM, Correa A. Patterns in the prevalence of congenital heart defects, metropolitan Atlanta, 1978 to 2005. Birth Defects Res Part A-Clin Mol Teratol. 2013; 97(2):87–94. https://doi.org/10.1002/bdra.23111 PMID: 2340870.

8. Shaw GM, Omaile CY, Wasserman CR, Tolarova MM, Lammier EJ. MATERNAL PERICONCEPTIONAL USE OF MULTIVITAMINS AND REDUCED RISK FOR CONotruncal Heart-Defects AND LIMB DEFICIENCIES AMONG OFFSPRING. Am J Med Genet. 1995; 59(4):536–45. https://doi.org/10.1002/ajmg.1320590428 PMID: 8585581.

9. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol. 1998; 78(2):151–61. https://doi.org/10.1016/s0301-2115(98)00061-x PMID: 9622312.

10. Botto LD, Muliniare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol. 2000; 151(9):878–84. PMID: 10791560.

11. Correa A, Botto L, Liu YC, Muliniare J, Erickson JD. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects? Pediatrics. 2003; 111(5):1146–51. PMID: 12732128.

12. Czeizel AE, Dobo M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res Part A-Clin Mol Teratol. 2004; 70(11):853–61. https://doi.org/10.1002/bdra.20086 PMID: 15523663.

13. van Beynum IM, Kapusta L, Bakker MK, den Heijer M, Blom HJ, de Walle HEK. Protective effect of periconceptional folic acid on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J. 2010; 31(4):464–71. https://doi.org/10.1093/eurheartj/ehp479 PMID: 19952004.

14. Bean LJH, Allen EG, Tinker SW, Hollis ND, Locke AE, Druschel C, et al. Lack of Maternal Folic Acid Supplementation Is Associated with Heart Defects in Down Syndrome: A Report from the National Down Syndrome Project. Birth Defects Res Part A-Clin Mol Teratol. 2011; 91(10):885–93. https://doi.org/10.1002/bdra.22848 PMID: 21987466.

15. Csaky-Szunyogh M, Vereczkey A, Kosa Z, Gerencser B, Czeizel AE. Risk and Protective Factors in the Origin of Conotruncal Defects of Heart-A Population-Based Case-Control Study. Am J Med Genet A. 2013; 161(10):2444–52. https://doi.org/10.1002/ajmg.a.36118 PMID: 23950097.

16. Li XY, Li SL, Mu DZ, Li Z, Li YL, Lin Y, et al. The association between periconceptional folic acid supplementation and congenital heart defects: A case-control study in China. Prev Med. 2013; 56(6):385–9. https://doi.org/10.1016/j.ypmed.2013.02.019 PMID: 23480969.

17. Csaky-Szunyogh M, Vereczkey A, Kosa Z, Urban R, Czeizel AE. Association of maternal diseases during pregnancy with the risk of single ventricular septal defects in the offspring—a population-based case-control study. J Matern-Fetal Neonatal Med. 2013; 26(8):738–47. https://doi.org/10.3109/14767058.2012.755170 PMID: 23205869.

18. Vereczkey A, Kosa Z, Csaky-Szunyogh M, Czeizel AE. Isolated atroventricular canal defects: Birth outcomes and risk factors: A population-based hungarian case-control study, 1980–1996. Birth Defects Res Part A-Clin Mol Teratol. 2013; 97(4):217–24. https://doi.org/10.1002/bdra.23124 PMID: 23554238.

19. Csaky-Szunyogh M, Vereczkey A, Kosa Z, Gerencser B, Czeizel AE. Risk Factors in the Origin of Congenital Left-Ventricular Outflow-Tract Obstruction Defects of the Heart: A Population-Based Case-
Control Study. Pediatr Cardiol. 2014; 35(1):108–20. https://doi.org/10.1007/s00246-013-0749-6 PMID: 23843102.

20. Hobbs CA, MacLeod SL, James SJ, Cleves MA. Congenital Heart Defects and Maternal Genetic, Metabolic, and Lifestyle Factors. Birth Defects Res Part A Clin Mol Teratol. 2011; 91(4):195–203. https://doi.org/10.1002/bdra.20784 PMID: 21384532.

21. Scanlon KS, Ferencz C, Loefredo CA, Wilson PD, Correa-Vilaseñor A, et al. Preconceptional Folate Intake and Malformations of the Cardiac Outflow Tract. Epidemiology. 1998; 9(1):95–8. PMID: 9430276.

22. Werler MM, Hayes C, Louti C, Shapiro S, Mitchell AA. Maternal smoking and congenital heart defects. Pediatrics. 2008; 121(4):E810–E6. https://doi.org/10.1542/peds.2007-1519 PMID: 18381510.

23. Williams LJ, Correa A, Rasmussen S. Maternal lifestyle factors and risk for ventricular septal defects. Birth Defects Res Part A Clin Mol Teratol. 2004; 70(2):59–64. PMID: 14991912.

24. Leirgul E, Gildestad T, Nilsen RM, Fomina T, Brodwall K, Greve G, et al. Periconceptional Folic Acid Supplementation and Infant Risk of Congenital Heart Defects in Norway 1999–2009. Paediatr Perinat Epidemiol. 2015; 29(5):391–400. https://doi.org/10.1111/ppe.12212 PMID: 26211216.

25. Shaw GM, Carmichael SL, Yang W, Lammer EJ. Periconceptional Nutrient Intakes and Risks of Conotruncal Heart Defects. Birth Defects Research Part A- Clinical and Molecular Teratology. 2010; 88(3):144–51. https://doi.org/10.1002/bdra.20648 PMID: 20063270.

26. Smets DM, Rakhsh andehroo M, Verkleij-Hagoort AC, de Vries JHM, Ursem NTC, de Jonge R, Hop WCJ, Steegers-Theunissen RPM. Dietary intake of B-vitamins in mothers born a child with a congenital heart defect. European Journal of Nutrition. 2006; 45(8):478–86. https://doi.org/10.1007/s00394-006-0622-y PMID: 17124548.

27. Qiu J, He X, Cui H, Zhang C, Zhang H, Dang Y, et al. Active Smoking and Preterm Birth in Urban China. American Journal of Epidemiology. 2014; 180(1):94–102. https://doi.org/10.1093/aje/kwu092 PMID: 24838804.

28. Wang Y, Zhao N, Qiu J, He X, Zhou M, Cui H, et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. European Journal of Clinical Nutrition. 2015; 69(10):1145–50. https://doi.org/10.1038/ejcn.2014.295 PMID: 25626412.

29. Liu X, Lv L, Zhang H, Zhao N, Qiu J, He X, et al. Folic acid supplementation, dietary folate intake and risk of preterm birth in China. Eur J Nutr. 2016; 55(4):1411–22. Epub 2015/07/04. https://doi.org/10.1007/s00394-015-0959-1 PMID: 26138063.

30. Institute of Nutrition and Food Hygiene, Chinese Academy of Preventive Medicine. Table of Food Components (national representative values). Beijing: People’s Hygiene Press; 1999.

31. Fekete K, Bertl C, Cetin I, Hermoso M, Koletzko BV, Decsi T. Perinatal folate supply: relevance in health outcome parameters. Matern Child Nutr. 2010; 6:23–38. https://doi.org/10.1111/j.1740-8709.2010.00261.x PMID: 22296249.

32. Rosenquist TH. Folate, Homocysteine and the Cardiac Neural Crest. Dev Dyn. 2013; 242(3):201–18. https://doi.org/10.1002/dvdy.23922 PMID: 23335187.

33. Stoller JZ, Epstein JA. Cardiac neural crest. Seminars in Cell & Developmental Biology. 2005; 16(6):704–15. https://doi.org/10.1016/j.semcdb.2005.06.004 PMID: 16054405.

34. Zhang Y, Riehle-Colarusso T, Correa A, Li S, Feng X, Gindler J, et al. Observed prevalence of congenital heart defects from a surveillance study in China. Journal of Ultrasound in Medicine: official journal of the American Institute of Ultrasound in Medicine. 2011; 30(7):989–95. Epub 2011/06/28. PMID: 21705732.

35. Liu F, Yang YN, Xie X, Li XM, Ma X, Fu ZY, et al. Prevalence of Congenital Heart Disease in Xinjiang Multi-Ethnic Region of China. PLoS One. 2015; 10(8):e0133961. Epub 2015/09/01. https://doi.org/10.1371/journal.pone.0133961 PMID: 26317413.
39. Xie D, Yang T, Liu Z, Wang H. Epidemiology of Birth Defects Based on a Birth Defect Surveillance System from 2005 to 2014 in Hunan Province, China. PLoS One. 2016; 11(1):e0147280. Epub 2016/01/27. https://doi.org/10.1371/journal.pone.0147280 PMID: 26812057.

40. Li H, Ge J. Cardiovascular diseases in China: Current status and future perspectives. IJC Heart & Vasculature. 2015; 6:25–31. https://doi.org/10.1016/j.ijcha.2014.10.002 PMID: 28785622.